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Abstract ATP-sensitive potassium channels ( K A T P ) are widely 
expressed and yet little is known about the mechanisms 
regulating their expression. Here we report that expression of 
chick heart Kir6.1 is regulated by channel activators. Activation 
of K A T P with either ATP depletion or pinacidil, up-regulated 
Kir6.1 mRNA 1.8- to 2.4-fold in cultured ventricular myocytes as 
measured by competitive PCR. Pinacidil treatment also in-
creased Kir6.1 protein as detected using an antibody to Kir6.1. 
Glibenclamide, a K A T P inhibitor, completely blocked the 
pinacidil-induced increase in Kir6.1 levels. It appears that 
Kir6.1 is up-regulated by an unknown signal transduction 
pathway initiated by K A T P opening. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
ATP-sensitive K + channels ( K A T P , e.g. Kir6.n) are inwardly 
rectifying two-transmembrane domain channels first described 
in heart but also found in other tissues including pancreas, 
brain, smooth muscle and skeletal muscle [1-4]. A distinguish-
ing feature of K A T P channels is that their activity is inhibited 
by typical intracellular A T P concentrations, but stimulated 
when A T P levels diminish [1]. Ra t Kir6.1 ( U K A T P - 1 ) is a can-
didate cardiac K A T P that is highly expressed in heart [3], while 
two other cloned K A T P candidates, Kir6.2 and IRK3(HIT) , 
are not [5,6]. K A T P is postulated to be an important coupler 
between energy state and electrical excitability in cells [7]. The 
physiological roles of K A T P channels in most tissues are not 
understood. In beta cells of the pancreas this pathway couples 
glucose metabolism with insulin secretion [8]. In heart, de-
creasing A T P levels (e.g. via hypoxia) opens K A T P causing 
K+ efflux, thus stabilizing membrane potential and perhaps 
protecting cells against further damage from voltage-activated 
Ca 2 + entry [9,10]. 
Little is known about the mechanisms that regulate the 
expression of inwardly rectifying potassium channels (Kir). 
We have previously shown that KATP-associated sulfonylurea 
receptors are up-regulated in chick heart cells both by recep-
tor ligands and by channel openers such as pinacidil [11]. In 
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addition, the G-protein-coupled inwardly rectifying K+ chan-
nels, G I R K 1 and G I R K 4 , are down-regulated in ovo follow-
ing muscarinic acetylcholine receptor activation [12]. 
Although the mechanisms underlying these events are not 
yet known, the results suggest that channel activity can regu-
late channel and channel-associated protein expression. These 
observations led us to ask whether channel activity mediated 
by chemical modulators also affects channel expression. These 
questions have special significance since potassium channel 
modulators are used to treat various disorders including dia-
betes, hypertension and asthma. For example, glibenclamide, 
a specific K A T P inhibitor, is used to treat non-insulin-depend-
ent diabetes mellitus [8] and pinacidil, a K A T P opener, is used 
to treat hypertension [13]. Here we report the partial cloning 
of an avian ATP-sensitive potassium channel, Kir6.1, and the 
regulation of its expression by channel activators. These stud-
ies represent some of the first aimed at defining these mecha-
nisms at the molecular level. 
2. Materials and methods 
2.1. Cloning of chick Kir6.1 
Total RNA isolated from 9-day embryonic chick heart by a one-
step method [14] was subjected to reverse transcription according to 
the manufacturer's protocol (Life Technologies). Polymerase chain 
reaction (PCR) was performed using degenerate primers matching 
the N-terminal (7-IIPEEYV-13: AT(ACT)AT(ACT)CCIGA(AG)-
GA(AG)TA(CT)GT) and the putative pore-forming domain (138-
QVTIGFG-144: CC(AG)AAICC (AGT)AT(ACGT)GTIAC(CT)TG) 
of the rat Kir6.1 [3] at a 55°C annealing temperature for 30 cycles. 
The major amplified product was 400 bp in agreement with the ex-
pected size based on the rat sequence and was subcloned into Blue-
script II SK(-) (Stratagene) at the EcoRV site. The 363 bp DNA 
sequence (Applied Biosystems 373 DNA Sequencer) with the primer 
sequences removed for fidelity was deposited into the GenBank with 
the accession number U92977. 
2.2. Northern blot analysis 
Total RNA (25 (ig/lane) from chick tissues was subjected to North-
ern blot analysis with 5X106 cpm/ml [a-32P]dATP-labeled chick 
Kir6.1 [15,16]. After hybridization at 42° for 16 h and high-stringency 
washing at 65°, the blots were exposed to Kodak X-omat film. As an 
internal control, blots were stripped and hybridized with a ribosomal 
L-27 probe following the same procedure [17]. 
2.3. Cell culture 
Homogeneous cultures of myocytes were prepared from 8-day chick 
embryo ventricles and cultured essentially as described except the 
medium was supplemented with 10% horse serum [11,18]. Cells were 
maintained for 2 days before the medium was changed and the cells 
were maintained for 1 more day before drug treatments were initiated. 
Cromakalim, diazoxide, pinacidil and glibenclamide were prepared as 
stock solutions in 60% DMSO. Control cells were treated with equal 
final concentrations of DMSO. The ATP level of cultured cells was 
measured using an ATP assay kit based on the luciferin-luciferase 
reaction (Calbiochem, La Jolla, CA) using the manufacturer's proto-
col. Reaction products were quantitated by liquid scintillation. 
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2.4. Competitive RT-PCR 
Competitive reverse transcription-PCR (RT-PCR) was used for 
mRNA quantification based on the linear relationship of Log(Pt/Pc) 
vs. LogNc0 [19]. Pt and Pc are the amounts of the final products 
amplified from the target and the competitor DNAs, and Nt° and 
Nc° are their starting molecule numbers, respectively. Relative 
LogNt0 is determined from the shift in x-intercept of the plots be-
tween control and treatment groups. The competitors for Kir6.1 and 
L27 were constructed by inserting a PCR-amplified 220 bp chick 
GIRK4 fragment (70-295 nt, Genbank #U71060) into the Styl site 
of Kir6.1 and L27 cloned in Bluescript. The RT-PCR primers for 
Kir6.1 were designed from 17-FAAENL-22 and 118-VTCVRS-121, 
a region which, in rat, distinguishes Kir6.1 from Kir6.2 (see Fig. 1). 
Single-stranded cDNA competitors were added with the reverse-tran-
scribed native templates for competitive RT-PCR. The products were 
subjected to Southern analysis using [a-32P]dATP-labeled chick Kir6.1 
as described above and quantitated by scanning densitometry (Ultro-
scan XL, Pharmacia). To normalize for differences both in RNA 
isolation from cultures and in the efficiency of reverse transcription, 
levels of ribosomal L27 mRNA were determined similarly as an in-
ternal control. 
2.5. Immunoblot detection of proteins 
Cultured cardiomyocytes were homogenized in PBS (mM: NaCl 
13.7, KC1 0.27, Na2HP04 0.81 and KH 2P0 4 0.15) containing l mM 
EDTA-Na2, 1 mM iodoacetamide, 200 uM PMSF, 5 Ug/ml trypsin 
inhibitor, 5 ug/ml pepstatin A and 1 ug/ml leupeptin. Membranes 
were collected by centrifugation and resuspended in the homogeniza-
tion buffer and an aliquot from each sample was used for protein 
determination by a modified Lowry method [11]. Protein (30 ug/ 
lane) was subjected to SDS-PAGE and transferred to nitrocellulose 
membranes as previously described [20]. The membranes were rever-
sibly stained by Ponceau S to ensure equivalent protein transfer 
among samples. The membranes were blocked with 5% BSA and 
incubated overnight at 4°C with a polyclonal rabbit anti-rat Kir6.1 
IgG (1:6000). This antibody was raised against a peptide (a.a. 397-
406) of rat Kir6.1 [3] and its binding to rat Kir6.1 on immunoblots is 
competed for by the immunizing peptide (Inagaki and Seino, manu-
script in preparation). Antibody-antigen complexes were visualized 
using enhanced chemiluminescence according to the manufacturer's 
instructions (Amersham, Arlington Heights, IL) and quantitated by 
scanning densitometry. Data were analyzed using a one-sided Stu-
dent's /-test. 
2.6. Materials 
Embryonated chick eggs (White Leghorn) were obtained from 
Gawlak Farms (Lawton, NY). The polyclonal anti-Kir6.1 antibody 
was generously provided by Dr. S. Seino (Chiba University School of 
Medicine, Japan). Cell culture reagents, molecular weight standards, 
M-MLV reverse transcriptase, restriction enzymes and Taq DNA pol-
ymerase were from Life Technologies Inc. (Grand Island, NY). Cro-
makalim, 2-deoxy-D-glucose, leupeptin, iodoacetamide and oligomy-
cin were from Sigma Chemical Co. (St. Louis, MO). Diazoxide and 
pinacidil were from RBI (Natick, MA) and glibenclamide was from 
Aldrich (Milwaukee, WI). Trypsin inhibitor and pepstatin A were 
from Boehringer Mannheim (Indianapolis, IN). Sources of other re-
agents were as previously described [20,21]. 
3. Results 
3.1. Cloning and expression of chick Kir6.1 
In order to obtain the chick Kir6.1 homologue, RT-PCR 
was used to obtain a clone which was sequenced from both 
strands and found to contain an open reading frame that 
encoded a protein fragment of 135 amino acids which was 
82% identical to rat Kir6.1 and 68% identical to rat Kir6.2 
[22] and covered one-third of the total coding region (Fig. 
1A). The chick Kir6.1 had just 41 and 46% identity with chick 
GIRK4 (Lu and Halvorsen, unpublished) and GIRK1 [23], 
respectively, over this same region. The most diverse region 
between avian and mammalian Kir6.1 was the extracellular 
loop between the first transmembrane domain (Ml) and the 
pore-forming region (H5). Northern analysis revealed a single 
3.6kb(±0.1,w = 3) species in chick heart, skeletal muscle and 
brain (Fig. IB). 
3.2. Regulation of Kir6.1 mRNA by channel modulators 
We previously showed that chronic treatment with KATP 
openers (e.g. pinacidil) or the inhibitor, glibenclamide, up-reg-
ulates glibenclamide receptors in cultured chick heart cells 
[11]. Therefore, we tested if channel activity also regulates 
the expression of KATP- In order to enhance the detection 
sensitivity in cultured cells, Kir6.1 mRNA was quantitated 
by competitive RT-PCR (Fig. 2). Treatment of ventricular 
myocytes with pinacidil (50 u,M, 12 h) caused a nearly 2.5-
fold up-regulation of Kir6.1 mRNA (Fig. 3A). This is a con-
centration of pinacidil that is known from electrophysiological 
studies to activate KATP [24,25]. The KATP inhibitor gliben-
clamide (30 nM) prevented the up-regulation of Kir6.1 
mRNA by pinacidil (Fig. 3A). This glibenclamide concentra-
tion was about 30-fold higher than its K^ for receptor binding 
as previously determined [11]. Glibenclamide alone induced a 
40% decrease of Kir6.1 mRNA (Fig. 3A). Therefore, activa-
tion of KATP was accompanied by an increase in Kir6.1 
mRNA and blockade of channel function was followed by a 
decrease in mRNA. 
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Fig. 1. Partial amino acid sequences of chick Kir6.1 with rat Kir6.1 
and Kir6.2 and tissue distribution of chick Kir6.1. A: Alignment of 
deduced amino acid sequences in single-letter code. Locations of 
RT-PCR primers are indicated by bold typeface. The putative first 
transmembrane domain (Ml) and the pore-forming region (H5) are 
indicated by lines above the residues. Residues that are non-identi-
cal with chick Kir6.1 are shown below the chick Kir6.1 sequence 
and gaps are indicated by dashes. The numbers at the right indicate 
the location of the last residue of rat Kir6.1 in each row. B: North-
ern blot of total RNA (25 u,g) from 9-day chick embryonic tissues 
was hybridized with a 32P-labeled chick Kir6.1 cDNA probe as de-
scribed in Section 2. Upper panel: A 3.6 kb signal was detected in 
RNA from ventricles (V), skeletal muscle (SK) and brain (BR). 
Lower panel: A cDNA probe for L27 ribosomal RNA was used as 
a control for RNA loading. 
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3.3. Regulation of Kir6.1 mRNA by ATP depletion 
One explanation for the up-regulation of Kir6.1 mRNA by 
pinacidil and its blockade by glibenclamide was that KATP 
opening initiated the regulation. To further test this we deter-
mined if activating KATP through lowering cellular ATP [26] 
also regulates Kir6.1. Ventricular myocytes were treated for 3 
h with the metabolic inhibitors oligomycin (0.2 |4,g/ml) and 2-
deoxy-D-glucose (5 mM), which decreased intracellular ATP 
concentrations to 0.2 mM from 1 mM (data not shown). 
Kir6.1 mRNA was up-regulated about 1.8-fold under these 
conditions of metabolic stress (Fig. 3B). Thus, two different 
treatments that activate KATP channels, either pinacidil or 
lowered ATP levels, each resulted in higher channel mRNA 
levels. 
—540 
- 3 2 0 
—540 
—320 
Fig. 2. Competitive RT-PCR analysis of Kir6.1 mRNA. A: Total 
RNA from control (CON) and pinacidil (PIN) treated (50 uM for 
12 h) chick ventricle cultures was subjected to reverse transcription 
followed by competitive RT-PCR with increasing amounts from 
right to left of a competitor (c, in arbitrary units, 540 bp) and a 
constant amount of target Kir6.1 (t, 320 bp). Shown is a Southern 
blot of the PCR products. Typically, the amount of 'c' ranged from 
1 to 16 fg per reaction. B: The PCR products from control (•) and 
pinacidil (■) treated ventricle cells from the experiment shown in 
(A) were quantitated by densitometry and plotted as described in 
Section 2. In this experiment a 1.8-fold increase was detected in 
samples from PIN-treated cells. 
Fig. 3. Regulation of Kir6.1 mRNA by channel activity. A: Chick 
ventricle cells were cultured for 3 days and treated with the indi-
cated modulators for the final 12 h. Total RNA was isolated for 
competitive RT-PCR and mRNA levels were determined as in Fig. 
2. Shown are the means ± SEM of n determinations expressed as a 
percent of the value from vehicle-treated cells (CTRL) after normal-
ization to L27. PIN: pinacidil 50 |xM, « = 6; GLIB: glibenclamide, 
30 nM, « = 3; PIN+GLIB: n = 3 (p<0.25). (B) Cultured cells as in 
(A) were treated with oligomycin (0.2 ug/ml) plus 2-deoxy-D-glucose 
(5 mM) for 3 h for ATP depletion (-ATP, n = 3) and competitive 
RT-PCR was performed to determine Kir6.1 mRNA levels as in 
(A). *P< 0.005 compared to control; **P< 0.025 compared to con-
trol. 
3.4. Regulation of Kir6.1 protein by .KATP channel modulators 
In order to determine if the changes in Kir6.1 mRNA in-
duced by channel modulators also resulted in changed protein 
expression, we used immunoblotting with an anti-rat Kir6.1 
antibody. A single 47 ± 1 kDa in — 3) signal was detected in 
chick heart cells (Fig. 4A) and no proteins were detected when 
non-immune rabbit serum was used as a negative control 
(data not shown). A single 47 kDa protein was also detected 
in samples prepared from neonatal rat heart (data not shown). 
Treatment of ventricular myocytes with pinacidil induced an 
increase of nearly 2-fold in Kir6.1 protein which was com-
pletely inhibited by co-administration with glibenclamide 
(Fig. 4B). Glibenclamide treatment alone for 24 h appeared 
to cause a small decrease in Kir6.1 but the result was not 
statistically significant (Fig. 4B). An increase in Kir6.1 protein 
similar to that seen with pinacidil was also observed after 
treatment of cells for 24 h with two other KATP channel acti-
vators, diazoxide and cromakalim (Fig. 4A). Therefore, the 
increase in Kir6.1 mRNA seen following treatment with chan-
nel openers was accompanied by a similar increase in Kir6.1 
protein. 
4. Discussion 
We have shown here that the expression of a cardiac KATP 
channel is up-regulated after channel activation. Kir6.1 
mRNA and/or protein was up-regulated by several different 
channel openers, pinacidil, cromakalim and diazoxide. All 
three openers share a similar function in opening KATP, but 
they have different target sites and probably trigger different 
transducers in activating KATP [3,24,27,28]. Both pinacidil 
and diazoxide have been shown to activate exogenously ex-
pressed Kir6.1 [29,30]. Further, activation of KATP by ATP 
depletion from metabolic inhibitors also up-regulated Kir6.1 
mRNA. The effects of pinacidil were blocked in the presence 
of glibenclamide which, at the concentration used, is a selec-
tive KATP inhibitor [2]. Together, these results support a hy-
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Fig. 4. Regulation of Kir6.1 protein by channel activity. A: Cul-
tured cardiomyocytes were treated in duplicate with the indicated 
reagents for 24 h. Membrane proteins were analyzed by immuno-
blotting with anti-Kir6.1 antibody and visualized as described in 
Section 2. Lanes 1-2, control; lanes 3^1, glibenclamide, 30 nM; 
lanes 5-6, pinacidil, 50 |xM+glibenclamide, 30 nM; lanes 7-8, pina-
cidil, 50 uM; lanes 9-10, cromakalim, 50 uM; lanes 11-12, diazo-
xide, 50 uJVI. The bars indicate the location of 43 and 68 kDa pro-
tein standards. B: Immunoblot results of Kir6.1 protein in control 
and treated cardiomyocytes as in (A) were quantitated and the 
mean±SEM (« = 3) as a percent of control levels were plotted. 
CTRL, vehicle treated; PIN: pinacidil 50 |xM; GLIB; glibenclamide 
30 nM; PIN+GLIB: pinacidil 50 uM+glibenclamide 3 0 n M 
(p<0.25). *P<0.025 compared to control; **P<0.1 compared to 
control. 
pothesis that opening of K A T P , including Kir6.1, is a common 
event in triggering an as yet unknown pathway to increase 
Kir6.1 expression. 
Recent reports indicate that a K A T P complex can be com-
posed of either Kir6.1 or 6.2 and a sulfonylurea receptor 
(SUR1 or 2). The sensitivity to A T P and channel modulators 
appears to be primarily determined by the SUR component 
[24,29-31]. We previously showed that cardiac sulfonylurea 
receptors, measured by [3H]glibenclamide binding, are up-
regulated by both pinacidil and glibenclamide [11]. While 
here we found that Kir6.1 was up-regulated by pinacidil, gli-
benclamide had only modest effects on Kir6.1 expression. 
Therefore, the two components of the complex can be regu-
lated either coordinately or independently. The effect of pina-
cidil on both sulfonylurea receptors and Kir6.1 might be 
through regulation of K A T P activity, while the effect of gli-
benclamide on sulfonylurea receptors might be through a li-
gand-sulfonylurea receptor interaction. 
This is the first report showing potassium channel up-reg-
ulation by channel activators. An increased expression of 
K A T P would result in an increased channel density which 
may enhance its protective effects during hypoxia or ischemia. 
Therefore, it is important to understand the mechanisms that 
regulate expression of these channels. Down-regulation of so-
dium channels by neurotoxin activation and G-protein-
coupled potassium channels by acetylcholine receptor activa-
tion has been reported [12,32]. In the latter case, the down-
regulation of potassium channels could result from desensiti-
zation of channels after chronic exposure to muscarinic ago-
nists. This would correlate with our treatment of cells with 
glibenclamide to inhibit K A T P activity that appears to result in 
slight down regulation of Kir6.1. However, K A T P activation 
by chemical activators or by lowered A T P may initiate path-
ways not leading to desensitization and thus resulting in the 
up-regulation of the Kir6.1 channel. The pathway(s) leading 
from K A T P activity to the regulation of Kir6.1 expression is 
not yet defined, but may represent a mechanism also impor-
tant for regulating other channels. 
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